Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARW...
Saved in:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/11/1/e004857.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832575577672908800 |
---|---|
author | Arthur Kavanaugh Paul Emery René Westhovens Mark C Genovese Kevin L Winthrop Rieke Alten Dick de Vries Lorenzo Dagna Patrick Verschueren Maria Greenwald Regina Cseuz Robin Besuyen Vikas Modgill Ly Huong Le |
author_facet | Arthur Kavanaugh Paul Emery René Westhovens Mark C Genovese Kevin L Winthrop Rieke Alten Dick de Vries Lorenzo Dagna Patrick Verschueren Maria Greenwald Regina Cseuz Robin Besuyen Vikas Modgill Ly Huong Le |
author_sort | Arthur Kavanaugh |
collection | DOAJ |
description | Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARWIN 2 (filgotinib monotherapy) trials could enrol. Patients received filgotinib 200 mg/day, except 15 men who received filgotinib 100 mg/day. The primary endpoints were safety and tolerability, which were assessed by the incidence of treatment-emergent adverse events (TEAEs). Safety and efficacy analyses included all enrolled patients who received ≥1 dose of filgotinib in DARWIN 3.Results 739 patients entered the LTE. The total patient-years of exposure (PYE) to filgotinib was 3706.3 years; the mean exposure duration was 259.8 weeks. 497 patients (67.3%) discontinued prematurely (including 266 TEAEs and 172 withdrawals due to the patient’s decision or ‘sponsor request’). Overall exposure-adjusted incidence rate (EAIR) was 67 (95% CI 62 to 72.2)/100 PYE for TEAEs and 3.8 (95% CI 3.2 to 4.5)/100 PYE for serious TEAEs. EAIR of infections was 23.3 (95% CI 21.2 to 25.6)/100 PYE, 1.3 (95% CI 0.9 to 1.7)/100 PYE for serious infections and 1.3 (95% CI 0.9 to 1.7)/100 PYE for herpes zoster. EAIRs of major adverse cardiovascular events (0.19 (95% CI 0.8 to 0.39)/100 PYE) and malignancies (0.6 (95% CI 0.4 to 0.9)/100 PYE) were low. Disease response assessed using non-responder imputation plateaued at LTE week 12 before slowly declining over time, with overall American College of Rheumatology (ACR)20/50/70 response rates of 26.9%/20.2%/14.7% at week 396.Conclusion Filgotinib was well tolerated in patients with RA for up to 8 years. Safety and efficacy profiles were maintained in patients previously receiving either filgotinib plus methotrexate or filgotinib monotherapy. |
format | Article |
id | doaj-art-3f0bb0046b7e49cfb5c382af59c46704 |
institution | Kabale University |
issn | 2056-5933 |
language | English |
publishDate | 2025-01-01 |
publisher | BMJ Publishing Group |
record_format | Article |
series | RMD Open |
spelling | doaj-art-3f0bb0046b7e49cfb5c382af59c467042025-01-31T22:45:10ZengBMJ Publishing GroupRMD Open2056-59332025-01-0111110.1136/rmdopen-2024-004857Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension studyArthur Kavanaugh0Paul Emery1René Westhovens2Mark C Genovese3Kevin L Winthrop4Rieke Alten5Dick de Vries6Lorenzo Dagna7Patrick Verschueren8Maria Greenwald9Regina Cseuz10Robin Besuyen11Vikas Modgill12Ly Huong Le13School of Medicine, University of California San Diego, La Jolla, California, USAUniversity of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UKDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, BelgiumClinical Development, Gilead Sciences Inc, Foster City, California, USASchool of Medicine, Oregon Health and Science University, Portland, Oregon, USADepartment of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, GermanyClinical Development, Galapagos BV, Leiden, NetherlandsUnit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Department of Internal Medicine, IRCCS San Raffaele Hospital, Milan, ItalyDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, BelgiumDepartment of Rheumatology, Desert Medical Advances, Rancho Mirage, California, USADepartment of Rheumatology, Revita Reumatológiai Kft, Budapest, HungaryClinical Development, Galapagos BV, Leiden, NetherlandsMedical Safety, Galapagos GmbH, Basel, SwitzerlandBiostatistics, Galapagos NV, Mechelen, BelgiumObjectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARWIN 2 (filgotinib monotherapy) trials could enrol. Patients received filgotinib 200 mg/day, except 15 men who received filgotinib 100 mg/day. The primary endpoints were safety and tolerability, which were assessed by the incidence of treatment-emergent adverse events (TEAEs). Safety and efficacy analyses included all enrolled patients who received ≥1 dose of filgotinib in DARWIN 3.Results 739 patients entered the LTE. The total patient-years of exposure (PYE) to filgotinib was 3706.3 years; the mean exposure duration was 259.8 weeks. 497 patients (67.3%) discontinued prematurely (including 266 TEAEs and 172 withdrawals due to the patient’s decision or ‘sponsor request’). Overall exposure-adjusted incidence rate (EAIR) was 67 (95% CI 62 to 72.2)/100 PYE for TEAEs and 3.8 (95% CI 3.2 to 4.5)/100 PYE for serious TEAEs. EAIR of infections was 23.3 (95% CI 21.2 to 25.6)/100 PYE, 1.3 (95% CI 0.9 to 1.7)/100 PYE for serious infections and 1.3 (95% CI 0.9 to 1.7)/100 PYE for herpes zoster. EAIRs of major adverse cardiovascular events (0.19 (95% CI 0.8 to 0.39)/100 PYE) and malignancies (0.6 (95% CI 0.4 to 0.9)/100 PYE) were low. Disease response assessed using non-responder imputation plateaued at LTE week 12 before slowly declining over time, with overall American College of Rheumatology (ACR)20/50/70 response rates of 26.9%/20.2%/14.7% at week 396.Conclusion Filgotinib was well tolerated in patients with RA for up to 8 years. Safety and efficacy profiles were maintained in patients previously receiving either filgotinib plus methotrexate or filgotinib monotherapy.https://rmdopen.bmj.com/content/11/1/e004857.full |
spellingShingle | Arthur Kavanaugh Paul Emery René Westhovens Mark C Genovese Kevin L Winthrop Rieke Alten Dick de Vries Lorenzo Dagna Patrick Verschueren Maria Greenwald Regina Cseuz Robin Besuyen Vikas Modgill Ly Huong Le Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study RMD Open |
title | Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study |
title_full | Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study |
title_fullStr | Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study |
title_full_unstemmed | Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study |
title_short | Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study |
title_sort | safety and efficacy of filgotinib in patients with rheumatoid arthritis final results of the darwin 3 long term extension study |
url | https://rmdopen.bmj.com/content/11/1/e004857.full |
work_keys_str_mv | AT arthurkavanaugh safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT paulemery safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT renewesthovens safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT markcgenovese safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT kevinlwinthrop safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT riekealten safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT dickdevries safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT lorenzodagna safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT patrickverschueren safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT mariagreenwald safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT reginacseuz safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT robinbesuyen safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT vikasmodgill safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy AT lyhuongle safetyandefficacyoffilgotinibinpatientswithrheumatoidarthritisfinalresultsofthedarwin3longtermextensionstudy |